November 20, 2009 - Ironwood Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its Class A common stock. The number of shares to be offered and the price range for the offering have not yet been determined. View Full Article

November 9, 2009 - Ikano Therapeutics, Inc. (ITI) announced today that it has received orphan drug designation for midazolam in the acute treatment of certain forms of epileptic seizure known as cluster seizures or alternatively, as acute repetitive seizures. ITI has a nasally administered form of midazolam called ITI-111 in late stage clinical development that is aimed at the treatment of these specific seizure types in an outpatient setting where other routes of administration can be difficult or inappropriate. Orphan Drug status confers seven years of marketing exclusivity for medicines that meet specific criteria in the treatment of qualifying conditions and patient populations. View Full Article

October 27, 2009 - Bioconnect Systems, Inc. announced today that data from the Company's first clinical study will be presented this week at the ASN
Meeting in San Diego. Bioconnect’s implant platform, the Optiflow™, enhances a surgeon’s ability to create precise vascular connections. The initial indication is the creation
of an arteriovenous fistula needed for vascular access in dialysis patients. View Full Article

October 17, 2009 - Transave Inc., today reported additional positive clinical trial results on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections. The latest results along with previously reported data demonstrate significant clinical benefits and complete the company’s Phase II program in two indications – for the treatment of lung infections due to the bacterium, Pseudomonas aeruginosa in cystic fibrosis (CF) patients and non-CF bronchiectasis patients. View Full Article

September 10, 2009 - Tetraphase Pharmaceuticals Inc., a
biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology
announced today that it will present three (3) posters and deliver a slide presentation on
the synthesis and antibacterial activity of analogs from several novel classes of antibiotics
to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial
Agents and Chemotherapy (ICAAC) in San Francisco, CA. View Full Article

July 29, 2009 - Transave Inc. announced today that it has entered into a cooperative research and development agreement with the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to study ARIKACE™ (liposomal amikacin for inhalation) in patients with nontuberculous mycobacteria (NTM) lung infections. View Full Article

July 13, 2009 - Accuri Cytometers, Inc. today announced the completion of a $4
million Series D financing. The financing included current investors Fidelity Biosciences, Flagship
Ventures, Baird Venture Partners and Arboretum Ventures, as well as the InvestMichigan! Program comanaged
by Credit Suisse. Accuri will use the proceeds from the Series D financing to provide additional
working and growth capital to support the rapid market acceptance of the Accuri C6 Flow Cytometer®
System, a revolutionary product designed to bring the power of flow cytometry analysis to the laboratory
of every life science researcher, and the recently introduced Accuri CSampler™, an optional accessory
that adds user-friendly automation to the C6 system. View Full Article

April 21, 2009 - Transave, Inc., today reported completion of patient enrollment in a Phase II study evaluating the safety and efficacy of Arikace™ (liposomal amikacin for inhalation) in non-cystic fibrosis (CF) bronchiectasis patients. The results, which are expected to be available by mid-year, will shed new light on how this patient population responds to treatment. Presently, there are no approved treatments for the disease. View Full Article

April 14, 2009 - ViewRay Incorporated, a
medical device company, announces the close of the second tranche of their $25M Series
B financing. Funding was triggered by the company’s achievement of a major milestone
towards the development of their image guided cancer therapy device, the Renaissance™
System. The financing was led by OrbiMed Advisors and Fidelity Biosciences, and was
joined by Aisling Capital and Kearny Venture Partners. View Full Article